Association of Expression Levels or Activation Status of STAT3 with Treatment Outcomes of Sunitinib in Patients with Renal Cell Carcinoma.

Kazuhiro YamamotoTakuto HaraTsutomu NakagawaMidori HiraiHideaki MiyakeMasato FujisawaIkuko Yano

Published in: Targeted oncology (2019)

Activated STAT3 in tumor tissues shows a significant association with poor prognosis in patients with RCC who received sunitinib as a first-line therapy, and positive p-STAT3 expression could be a potential biomarker for refractoriness to sunitinib therapy.

Keyphrases

poor prognosis
renal cell carcinoma
long non coding rna
cell proliferation
metastatic renal cell carcinoma
gene expression
stem cells
binding protein
smoking cessation